KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Current Deferred Revenue (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Current Deferred Revenue for 17 consecutive years, with $95.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 30.66% to $95.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $95.0 million, a 30.66% decrease, with the full-year FY2025 number at $95.0 million, down 30.66% from a year prior.
  • Current Deferred Revenue was $95.0 million for Q4 2025 at Bristol Myers Squibb, down from $190.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $367.0 million in Q1 2021 to a low of $95.0 million in Q4 2025.
  • A 5-year average of $270.9 million and a median of $289.0 million in 2022 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: fell 3.68% in 2023, then crashed 50.0% in 2024.
  • Bristol Myers Squibb's Current Deferred Revenue stood at $330.0 million in 2021, then decreased by 12.42% to $289.0 million in 2022, then dropped by 5.19% to $274.0 million in 2023, then plummeted by 50.0% to $137.0 million in 2024, then crashed by 30.66% to $95.0 million in 2025.
  • Per Business Quant, the three most recent readings for BMY's Current Deferred Revenue are $95.0 million (Q4 2025), $190.0 million (Q3 2025), and $203.0 million (Q2 2025).